Overview

To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease

Status:
Recruiting
Trial end date:
2022-02-15
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.
Phase:
Phase 2
Details
Lead Sponsor:
Ocular Therapeutix, Inc.